SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc., a privately held life sciences company marketing a complete solution for detecting and counting large sets of target molecules in biological ...
SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research, today announced a strategic transaction to exclusively ...
SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the ...
SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, and OnRamp Bioinformatics, a provider of ...
NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the launch of a Single Cell Gene ...
NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced the commercial unveiling of the nCounter Pro Analysis System, the next ...
NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced the commercial launch of the nCounter® RNA:Protein ...
Personalized medicine has beomce a paradigm in lung cancer management; ~ 25–30% of advanced lung cancer patients could benefit from a targeted therapy. Several guidelines currently endorse routine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback